Literature DB >> 21862684

Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Carolyn M Klinge1, Brandie N Radde, Yoannis Imbert-Fernandez, Yun Teng, Margarita M Ivanova, Sabra M Abner, Alexandra L Martin.   

Abstract

Mucin 1 (MUC1) is a diagnostic factor and therapy target in lung adenocarcinoma. MUC1 C-terminal intracellular domain (CD) interacts with estrogen receptor (ER) α and increases gene transcription in breast cancer cells. Because lung adenocarcinoma cells express functional ERα and ERβ, we examined MUC1 expression and MUC1-ER interaction. Because blocking MUC1 CD with an inhibitory peptide (PMIP) inhibited breast tumor growth, we tested whether PMIP would inhibit lung adenocarcinoma cell proliferation. We report that MUC1 interacts with ERα and ERβ within the nucleus of H1793 lung adenocarcinoma cells in accordance with MUC1 expression. PMIP was taken up by H23 and H1793 cells and inhibited the proliferation of H1793, but not H23 cells, concordant with higher MUC1 protein expression in H1793 cells. Lower MUC1 protein expression in H23 does not correspond to microRNAs miR-125b and miR-145 that have been reported to reduce MUC1 expression. PMIP had no effect on the viability of normal human bronchial epithelial cells, which lack MUC1 expression. PMIP inhibited estradiol-activated reporter gene transcription and endogenous cyclin D1 and nuclear respiratory factor-1 gene transcription in H1793 cells. These results indicate MUC1-ER functional interaction in lung adenocarcinoma cells and that inhibiting MUC1 inhibits lung adenocarcinoma cell viability.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21862684      PMCID: PMC3213286          DOI: 10.1158/1535-7163.MCT-11-0381

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  45 in total

1.  MUC1 splice variants in human ocular surface tissues: possible differences between dry eye patients and normal controls.

Authors:  Yoannis Imbert; Douglas S Darling; Marcia M Jumblatt; Gary N Foulks; Erica G Couzin; Pamela S Steele; William W Young
Journal:  Exp Eye Res       Date:  2006-04-21       Impact factor: 3.467

Review 2.  Estrogen signaling via estrogen receptor {beta}.

Authors:  Chunyan Zhao; Karin Dahlman-Wright; Jan-Åke Gustafsson
Journal:  J Biol Chem       Date:  2010-10-18       Impact factor: 5.157

Review 3.  Membrane-associated estrogen receptor signaling pathways in human cancers.

Authors:  Richard J Pietras; Diana C Márquez-Garbán
Journal:  Clin Cancer Res       Date:  2007-08-15       Impact factor: 12.531

4.  Lung cancer mortality risk among breast cancer patients treated with anti-estrogens.

Authors:  Christine Bouchardy; Simone Benhamou; Robin Schaffar; Helena M Verkooijen; Gerald Fioretta; Hyma Schubert; Vincent Vinh-Hung; Jean-Charles Soria; Georges Vlastos; Elisabetta Rapiti
Journal:  Cancer       Date:  2011-01-24       Impact factor: 6.860

Review 5.  Sex and gender differences in lung cancer.

Authors:  Laura P Stabile; Jill M Siegfried
Journal:  J Gend Specif Med       Date:  2003

6.  The effects of sex steroid hormones and interleukin-1-beta on MUC1 expression in endometrial epithelial cell lines.

Authors:  A W Horne; E-N Lalani; R A Margara; J O White
Journal:  Reproduction       Date:  2006-04       Impact factor: 3.906

7.  miR-1226 targets expression of the mucin 1 oncoprotein and induces cell death.

Authors:  Caining Jin; Hasan Rajabi; Donald Kufe
Journal:  Int J Oncol       Date:  2010-07       Impact factor: 5.650

8.  Expression of MUC1, MUC2, MUC5AC, and MUC6 in atypical adenomatous hyperplasia, bronchioloalveolar carcinoma, adenocarcinoma with mixed subtypes, and mucinous bronchioloalveolar carcinoma of the lung.

Authors:  Hirokazu Awaya; Yukio Takeshima; Masahiro Yamasaki; Kouki Inai
Journal:  Am J Clin Pathol       Date:  2004-05       Impact factor: 2.493

9.  Human DF3/MUC1 carcinoma-associated protein functions as an oncogene.

Authors:  Yongqing Li; Derek Liu; Dongshu Chen; Surender Kharbanda; Donald Kufe
Journal:  Oncogene       Date:  2003-09-04       Impact factor: 9.867

Review 10.  MUC1, the renaissance molecule.

Authors:  S J Gendler
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.698

View more
  11 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  Interaction Between MUC1 and STAT1 Drives IFITM1 Overexpression in Aromatase Inhibitor-Resistant Breast Cancer Cells and Mediates Estrogen-Induced Apoptosis.

Authors:  Taylor E Escher; Asona J Lui; Eric S Geanes; Katherine R Walter; Ossama Tawfik; Christy R Hagan; Joan Lewis-Wambi
Journal:  Mol Cancer Res       Date:  2019-01-17       Impact factor: 5.852

Review 3.  MUC1 and metastatic cancer: expression, function and therapeutic targeting.

Authors:  Teresa M Horm; Joyce A Schroeder
Journal:  Cell Adh Migr       Date:  2013-01-09       Impact factor: 3.405

4.  Protumorigenic effects of mir-145 loss in malignant pleural mesothelioma.

Authors:  M Cioce; F Ganci; V Canu; A Sacconi; F Mori; C Canino; E Korita; B Casini; G Alessandrini; A Cambria; M A Carosi; R Blandino; V Panebianco; F Facciolo; P Visca; S Volinia; P Muti; S Strano; C M Croce; H I Pass; G Blandino
Journal:  Oncogene       Date:  2013-11-18       Impact factor: 9.867

5.  MUC1 drives c-Met-dependent migration and scattering.

Authors:  Teresa M Horm; Benjamin G Bitler; Derrick M Broka; Jeanne M Louderbough; Joyce A Schroeder
Journal:  Mol Cancer Res       Date:  2012-11-27       Impact factor: 5.852

6.  Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line.

Authors:  Natália R Costa; Paula Paulo; Thomas Caffrey; Michael A Hollingsworth; Filipe Santos-Silva
Journal:  PLoS One       Date:  2011-11-02       Impact factor: 3.240

7.  Origin of anti-tumor activity of the cysteine-containing GO peptides and further optimization of their cytotoxic properties.

Authors:  Irina I Tyuryaeva; Olga G Lyublinskaya; Ivan S Podkorytov; Nikolai R Skrynnikov
Journal:  Sci Rep       Date:  2017-01-16       Impact factor: 4.379

Review 8.  The Emerging Roles of miR-125b in Cancers.

Authors:  Ying Wang; Guilin Zeng; Yicheng Jiang
Journal:  Cancer Manag Res       Date:  2020-02-12       Impact factor: 3.989

9.  Overexpression of PELP1 in Lung Adenocarcinoma Promoted E2 Induced Proliferation, Migration and Invasion of the Tumor Cells and Predicted a Worse Outcome of the Patients.

Authors:  Dongmei Zhang; Jiali Dai; Yu Pan; Xiuli Wang; Juanjuan Qiao; Hironobu Sasano; Baoshan Zhao; Keely M McNamara; Xue Guan; Lili Liu; Yanzhi Zhang; Monica S M Chan; Shuwen Cao; Ming Liu; Sihang Song; Lin Wang
Journal:  Pathol Oncol Res       Date:  2021-04-02       Impact factor: 3.201

Review 10.  Comprehensive analysis of the mechanism and treatment significance of Mucins in lung cancer.

Authors:  Yue Ning; Hongmei Zheng; Yuting Zhan; Sile Liu; Yang Yang; Hongjing Zang; Jiadi Luo; Qiuyuan Wen; Songqing Fan
Journal:  J Exp Clin Cancer Res       Date:  2020-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.